Benefit of ventriculoperitoneal cerebrospinal fluid shunting and intrathecal chemotherapy in neoplastic meningitis: a retrospective, case-controlled study
- PMID: 21721878
- DOI: 10.3171/2011.5.JNS101768
Benefit of ventriculoperitoneal cerebrospinal fluid shunting and intrathecal chemotherapy in neoplastic meningitis: a retrospective, case-controlled study
Abstract
Object: Neoplastic meningitis (NM) is a debilitating and increasingly frequent neurological complication of cancer characterized by infiltration of tumor cells into the leptomeninges and the subarachnoid space. Although NM is rarely curable, combined intrathecal chemotherapy and focal radiation can improve disease-related symptoms and survival. Hydrocephalus occurs in a significant proportion of patients, is associated with poor prognosis and reduced quality of life, and usually precludes the use of intrathecal therapy.
Methods: Since January of 2005, the authors have used a combined treatment approach for patients with both NM and hydrocephalus that employs a subcutaneously placed reservoir connected in series to an on/off valve and a ventriculoperitoneal shunt for both diversion of CSF and injection of intrathecal chemotherapy. They conducted a retrospective, case-controlled study from 2 independent institutions to review their experience.
Results: Twenty-four patients with NM and hydrocephalus underwent placement of a CSF reservoir-on/off valve-ventriculoperitoneal shunt (RO-VPS) construct. There was no perioperative mortality, and there were only 2 minor complications. One shunt failure and no shunt-associated infections were observed over a median of 28 weeks of follow-up. Symptomatic improvement and improved performance status were seen in 20 patients (83.3%) and were sustained over 6 months. Eighteen patients received intraventricular chemotherapy without unexpected toxicity, and cytological responses were found in 11 patients (61.1%). Median progression-free and overall survival was 14 and 31 weeks, respectively. Compared with a contemporaneous comparison group of 24 demographically matched patients with NM who underwent CSF reservoir placement only, those who received RO-VPS constructs (p = 0.02) and had primary diagnosis of breast cancer (p = 0.04) had significant advantage in overall survival.
Conclusions: A combined RO-VPS system is safe and practical to install, results in symptomatic improvement in most patients, and allows uncomplicated and effective administration of intrathecal chemotherapy in patients with NM. Cerebrospinal fluid diversion surgery should be considered in NM patients in conjunction with intrathecal and systemic treatments.
Comment in
-
Neoplastic meningitis.J Neurosurg. 2011 Oct;115(4):728-9; discussion 729. doi: 10.3171/2011.4.JNS11492. Epub 2011 Jul 1. J Neurosurg. 2011. PMID: 21721876 No abstract available.
-
Neoplastic meningitis.J Neurosurg. 2012 Nov;117(5):979; author reply 979-80. doi: 10.3171/2012.2.JNS111993. Epub 2012 Sep 14. J Neurosurg. 2012. PMID: 22978543 No abstract available.
Similar articles
-
[Case of leptomeningeal carcinomatosis effectively treated with intrathecal chemotherapy using ventriculoperitoneal shunt].Rinsho Shinkeigaku. 2006 Jun;46(6):404-9. Rinsho Shinkeigaku. 2006. PMID: 16986702 Japanese.
-
Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen.Cancer. 1996 Apr 1;77(7):1315-23. doi: 10.1002/(SICI)1097-0142(19960401)77:7<1315::AID-CNCR14>3.0.CO;2-4. Cancer. 1996. PMID: 8608509 Clinical Trial.
-
A novel method for administering intrathecal chemotherapy in patients with leptomeningeal metastases and shunted hydrocephalus: case report.Neurosurgery. 2010 Sep;67(3 Suppl Operative):onsE306-7; discussion onsE307. doi: 10.1227/01.NEU.0000383138.78632.BA. Neurosurgery. 2010. PMID: 20679917
-
Leptomeningeal carcinomatosis originating from advanced gastric cancer--a report of three cases and review of the literatures.Fukuoka Igaku Zasshi. 2013 Nov;104(11):456-63. Fukuoka Igaku Zasshi. 2013. PMID: 24620642 Review.
-
Treatment modalities for leptomeningeal metastases.Semin Oncol. 2009 Aug;36(4 Suppl 2):S46-54. doi: 10.1053/j.seminoncol.2009.05.006. Semin Oncol. 2009. PMID: 19660683 Review.
Cited by
-
Neoplastic meningitis resulting from hematological malignancies: pharmacokinetic considerations and maximizing outcome.Clin Investig (Lond). 2011 Oct;1(10):1391-1402. doi: 10.4155/cli.11.115. Clin Investig (Lond). 2011. PMID: 22396850 Free PMC article.
-
Leptomeningeal carcinomatosis and breast cancer: a systematic review of current evidence on diagnosis, treatment and prognosis.Drugs Context. 2021 Oct 26;10:2021-6-6. doi: 10.7573/dic.2021-6-6. eCollection 2021. Drugs Context. 2021. PMID: 34745272 Free PMC article. Review.
-
Clinical outcome of cerebrospinal fluid shunts in patients with leptomeningeal carcinomatosis.World J Surg Oncol. 2019 Mar 27;17(1):59. doi: 10.1186/s12957-019-1595-7. World J Surg Oncol. 2019. PMID: 30917830 Free PMC article.
-
Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study.J Neurooncol. 2014 Sep;119(2):361-8. doi: 10.1007/s11060-014-1486-2. Epub 2014 Jun 19. J Neurooncol. 2014. PMID: 24942463
-
Leptomeningeal Carcinomatosis in Gastric Cancer: A Therapeutical Challenge.Biomark Insights. 2017 Mar 16;12:1177271917695237. doi: 10.1177/1177271917695237. eCollection 2017. Biomark Insights. 2017. PMID: 28469397 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials